# Antiproliferative activity of naphthoquinones and indane carboxylic acids from lapachol against a panel of human cancer cell lines

## Kenneth O. Eyong, Herve L. Ketsemen, Zhenze Zhao, Liqin Du, Aude Ingels, Veronique Mathieu, Alexander Kornienko, Kenneth G. Hull, et al.

ONLINE FIRST

🐴 Springer

Springer

**ORIGINAL RESEARCH**

# Antiproliferative activity of naphthoquinones and indane carboxylic acids from lapachol against a panel of human cancer cell lines

Kenneth O. Eyong[1,2] · Herve L. Ketsemen[2] · Zhenze Zhao[3] · Liqin Du[3] · Aude Ingels[4] · Veronique Mathieu[4] · Alexander Kornienko[3,5] · Kenneth G. Hull[1] · Gabriel N. Folefoc[2] · Sundarababu Baskaran[6] · Daniel Romo[1]

## Abstract

Lapachol (**1**) is a well-studied natural product isolated from plants of the *Bignoniaceae* family and demonstrates diverse biological effects. Historically, chemical transformation of the lapachol scaffold has yielded new derivatives with impressive biological activity and rich chemical diversity. β-lapachone (**2**), α-lapachone (**3**), and 2-acetylfuronaphthoquinone (**4**) are examples of analogs derived from lapachol that show superior antitumor activity compared with the natural product. In the present study, novel indane carboxylic acid: 2,2-dimethyl-2,3-dihydroindeno[1,2-b]pyran-4,5-dione (**9**) and methyl 5-hydroxy-2,2-dimethyl-2,3,4,5-tetrahydroindeno[1,2-b]pyran-5-carboxylate (**10**) and naphthoquinone derivatives were synthesized from lapachol with structural similarities to the antitumor lapachol derivatives. The synthesized compounds were evaluated for antiproliferative activities against a panel of human cancer cell lines including in vitro models for neuroblastoma, melanoma, glioblastoma, and non-small cell lung cancer. As expected, the most potent derivatives were those incorporating β-naphthoquinone and α-naphthoquinono[2,3-b]furan skeletons. Many of these compounds possessed nanomolar to single digit micromolar antiproliferative potency. However, the most interesting analog evaluated was the dione **9** with an indeno[1,2-b]pyran skeleton, which demonstrated potent cytotoxic activity. The current investigation identified several new lead compounds that could be used as starting points for anticancer drug discovery.

**Keywords** Lapachol · Naphthoquinone · Indane carboxylic acid · Cancer cell lines · Benzilic acid rearrangement

✉ Kenneth O. Eyong
  eyongkk@yahoo.com

1   Department of Chemistry and Biochemistry and the CPRIT Synthesis and Drug-Lead Discovery Laboratory, Baylor University, Waco, TX 76798, USA

2   Department of Organic Chemistry, Faculty of Science, University of Yaounde I, P.O. Box 812, Yaounde, Cameroon

3   Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA

4   Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium

5   Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., Stavropol 355009, Russian Federation

6   Department of Chemistry, Indian Institute of Technology Madras, Chennai 600 036, India

## Introduction

Natural products isolated from various traditional herbal plants have had a huge impact on the development of various lead compounds used in the treatment of health issues in societies throughout the world. The tremendous biodiversity of plants in tropical and subtropical regions has led to the identification of equally diverse chemical structures with a wide range of biological activity (Nepomuceno 2011). In 1882, the Italian scientist Emanuele Paterno reported on the isolation of lapachol (**1**) (Fig. 1) from a traditional herbal plant viz., *Tabebuia impetiginosa* (Mart. ex DC) Standl (Castellanos et al. 2009). The first detailed anticancer effects of lapachol (**1**) (Nepomuceno 2011) were evaluated in 1968 and this compound was shown to possess very potent effects toward cancerous tumors in rats (Hussain et al. 2007). Unfortunately, in 1974, the National Cancer Institute demonstrated in a phase I clinical trial that lapachol (**1**) was not an effective treatment of cancer due to lack of a therapeutic window and this essentially terminated further clinical research at the time. However, in 1980, in a

**Fig. 1** Structures of lapachol (**1**), β-lapachone (**2**), α-lapachone (**3**), 2-acetylfuronaphthoquinone (**4**)



## Results and discussion

### Chemical transformation

The aim of this study was to prepare new derivatives of lapachol that are structurally related to β-lapachone, α-lapachone, and 2-acetylfuronaphtoquinone with potentially enhanced biological activity. In addition, we sought to probe how changes to the stereochemistry and electronics of the core structures influence bioactivity. Finally, from previous studies, quinones represent a class of generally cytotoxic moieties, which lead to a variety of generally undesirable effects in vivo, including acute cytotoxicity, immunotoxicity, and carcinogenesis. Quinones, often considered nuisance pharmacophores (Dahlin et al. 2015), are Michael acceptors, and cellular damage can occur through alkylation of crucial cellular proteins and/or DNA. Alternatively, quinones are highly redox active molecules, which can engage in redox cycles with their semi-quinone radicals, leading to formation of reactive oxygen species (ROS), including superoxide, hydrogen peroxide, and ultimately the hydroxyl radical. Production of ROS can cause severe oxidative stress within cells through the formation of oxidized cellular macromolecules, including lipids, proteins, and DNA (Bolton et al. 2000; Monks et al. 1992). In a pharmacomodulation attempt to remove these quinone groups, orthoquinones were converted to indane carboxylic acids via benzilic acid rearrangement and to phenazines using a Schiff base reaction to avoid these potential pitfalls associated with drugs that possess a quinone moiety.

To obtain new derivatives for anticancer screening, lapachol (**1**) was treated with conc. $H_2SO_4$ at room temperature (rt) to afforded β-lapachone (**2**), which undergoes a benzilic acid rearrangement to yield compound **8** when treated with 3 N sodium hydroxide as previously described (Eyong et al. 2013). Treatment of **8** with diazomethane generated in situ from nitrosomethylurea (NMU) afforded an unexpected dione derivative **9** as the major compound alongside the expected methyl ester **10** (Scheme 1).

The dione **9** was obtained as a red solid (mp 178–180 °C) from silica gel purification by gradient elution (20 → 30%, hexane/ethyl acetate). The molecular formula was determined to be $C_{14}H_{12}O_3$ on the basis of LCMS (APCI$^+$) m/z Calcd for $C_{14}H_{13}O_3$ [M+H]$^+$ 229.08647, found 229.08606. The $^1H$ NMR spectrum (600 MHz, CDCl$_3$) of compound **9**

small study with nine patients from Nice with various cancers (liver, kidney, breast, prostate, and cervix), pure lapachol (**1**) demonstrated the ability to shrink tumors, reduce pain, and achieve complete remissions in three of the patients without significant adverse effects (Hussain et al. 2007).

This discovery and the fact that additional antitumor effects of lapachol (**1**) were found, led to it being considered a good candidate for derivatization to identify new lead compounds through structure–activity relationship (SAR) studies. Moreover, various lapachol analogs have been prepared and studied for the treatment of lung, breast, prostate, melanoma, leukemic, ovarian, glioblastoma, prostate, colon, and renal cancer (Hussain et al. 2007; Fiorito et al. 2014). In addition to its cytotoxic activity, lapachol (**1**) has also been shown to possess very broad biological effects including antibacterial, antiviral, analgesic, anti-inflammatory, and fungicidal activity (Hussain et al. 2007; Oliveira et al. 2002).

Derivatives of lapachol are also of interest due to their diverse biological properties recently identified. β-lapachone (**2**) and α-lapachone (**3**) isolated from *T. impetiginosa* (Castellanos et al. 2009) and 2-acetylfuronaphthoquinone (**4**) isolated from the Bignoniaceae *Newbouldia laevis* (Eyong et al. 2005) also possess unique properties. For example, β-lapachone (**2**) displays a broad spectrum of biological and pharmacological effects including antifungal, anti-inflammatory, anticancer, antibacterial, antiangiogenic, DNA damaging, and antitrypanocidal activity (Hussain et al. 2007; Queiroz et al. 2008; Rios-Luci et al. 2012; Li et al. 2000; Lim et al. 2015; Ramos-Perez et al. 2014; Perez-Sacau et al. 2007; Sunassee et al. 2013; da Silva et al. 2007). Interestingly, it has been reported that β-lapachone (**2**) is able to selectively induce cell death in various human cancer cells without killing non-transformed cells and in combination therapy with taxol it displays potent anticancer effects against many cultured cancer cells including ovarian, prostate, lung, breast, colon, melanoma, and pancreatic cell lines (Hussain et al. 2007). In addition, α-lapachone (**3**) has been shown to possess trypanocidal effects toward *Trypanosoma cruzi* and its analogs display antileishmanial activity toward *Leishmania amazonensis* and *L. braziliensis* (Souza-Silva et al. 2014), while 2-acetylfuronaphthoquinone (**4**) is a potential chemopreventive agent (Ueda 2005).

**Scheme 1** New indane derivatives from lapachol (**1**)

**Table 1** $^1$H and $^{13}$C NMR data (600 and 150 MHz) of compounds **9** and **10** (400 and 100 MHz) ($\delta_H$, CDCl$_3$, $J$ in Hz)

| Position | Compound 9 | | Compound 10 |
|---|---|---|---|
| | $^1$H | $^{13}$C | $^1$H |
| 2 | – | 93.8 | – |
| 3 | 2.95 (s, 2H) | 39.5 | 1.63 (t, $J = 8.4$, 2H) |
| 4 | – | 175.9 | 2.68 (t, $J = 8.4$, 2H) |
| 4a | – | 115.1 | – |
| 5 | – | 181.5 | – |
| 5a | – | 128.1 | – |
| 6 | 8.15 (m, 1H) | 129.5 | 8.05 (m, 1H) |
| 7 | 7.60 (m, 1H) | 132.0 | 7.69 (m, 1H) |
| 8 | 7.65 (m, 1H) | 134.6 | 7.69 (m, 1H) |
| 9 | 7.65 (m, 1H) | 124.7 | 8.05 (m, 1H) |
| 9a | – | 131.1 | – |
| 9b | – | 168.9 | – |
| 10 | 1.61 (s, 3H) | 28.6 | 1.29 (s, 3H) |
| 11 | 1.61 (s, 3H) | 28.6 | 1.29 (s, 3H) |
| 12 | – | – | – |
| 13 | – | – | 4.14 (s, 3H) |

exhibited signals indicative of four aromatic protons at $\delta_H$ 8.15 (1H, m), 7.65 (2H, m), and 7.60 (1H, m), a methylene group at $\delta_H$ 2.95 (2H, s) and two methyl groups at $\delta_H$ 1.61 (6H, s). The $^{13}$C NMR spectrum (150 MHz, CDCl$_3$) exhibited 13 carbon signals that were assigned by a DEPT from multiplicity edited HSQC experiment as four methine sp$^2$ at 134.6, 132.0, 129.5, and 124.7, one methylene at 39.5, two methyl at 28.6 appearing as a single peak, and seven carbon signals including six sp$^2$ carbon atoms at 181.5 (C=O), 175.9 (C=O), 168.9 (=C–O), 131.1 (C=C), 128.1 (C=C), 115.1 (C=C) and an sp$^3$ carbon atom at 93.8 (C–O). The $^1$H and $^{13}$C NMR data (Table 1) were assigned using $^1$H–$^1$H COSY, HSQC, and HMBC spectra (see Supporting Information). In the $^1$H–$^1$H COSY, correlations were observed between H-6 ($\delta_H$ 8.15, 1H, m) and H-7 (7.60, 1H, m), between H-7 (7.60, 1H, m) and H-8 (7.65, 1H, m), and between H-8 (7.65, 1H, m) and H-9 (7.65, 1H, m) indicating AA′BB′ spin system of four aromatic protons. HMBC spectrum showed correlations of H-3 ($\delta_H$ 2.95, 2H, s) with C-4 (175.9), C-9b (168.9), C-4a (115.1), C-2 (93.8),

C-10 (28.6), and C-11 (28.6) supporting H-3 connectivity in $^2$J or $^3$J and $^4$J. Decarboxylation followed by benzylic oxidation occurs under the reaction conditions or during workup to form dione **9**. Further investigations into the mechanism for the reaction resulting in compound **9** will be pursued.

Compound **10** was obtained as a white solid from silica gel purification by gradient elution ($2.5 \rightarrow 5\%$, hexane/ethyl acetate). The molecular formula was determined to be C$_{16}$H$_{18}$O$_4$ on the basis of HRMS (ESI-TOF) $m/z$ Calcd for C$_{16}$H$_{19}$O$_4$ [M+H]$^+$ 275.1283, found 275.1295. The $^1$H NMR spectrum (400 MHz, CDCl$_3$) of compound **10** exhibited signals indicative of four aromatic protons at $\delta_H$ 8.05 (2H, m) and 7.70 (2H, m), attributed to an AA′BB′ spin system. A singlet at 4.14 (3H, s) attributed to a methoxy group. Two set of triplets at 2.69 (2H, t, $J = 8.4$ Hz) and at 1.63(2H, t, $J = 8.4$ Hz) corresponding to two adjacent methylene groups. A singlet at $\delta_H$ 1.29 (6H, s) for two methyl groups. Compound **10** is the expected ester from previously reported carboxylic acid **8**. The $^1$H NMR spectra of compound **10** is very similar to compound **8** with just the appearance of the new methyl ester peak in compound **10**. See SI including a stacked spectra with compounds **8** and **10**.

Previously synthesized compounds **5**, **6**, **7**, **8**, **11–23** (Eyong et al. 2013, 2015a; Tanis et al. 1988), which are structurally related to α-lapachone, β-lapachone, and 2-acetylfuronapthoquinone were re-synthesized to evaluate their anticancer activities in a comprehensive panel of human cancer cell line assays. Lapachol (**1**) under the Hooker oxidation condition afforded nor-lapachol (**5**). Treatment of compound **5** with conc. H$_2$SO$_4$ afforded nor-β lapachone (**6**), which underwent benzilic acid rearrangement using 3 N NaOH to give hydroxy acid **7** (Eyong et al. 2013).

Lapachol also afforded 3-bromo-β-lapachone (**11**) upon bromination and the benzilic acid rearrangement of **11** provides compound **12** (Eyong et al. 2013). Finally, hydrogen peroxide oxidation of lapachol afforded the Hooker intermediate **13** which on esterification provided methyl ester **14** (Eyong et al. 2013).

In an attempt to obtain napthoquinones stereoselectively for SAR studies, lapachol (**1**) was converted to lomatiol (**15**) under allylic oxidation conditions (Tanis et al. 1988). Subsequent treatment of lomatiol with m-CPBA afforded

compounds **16** and **17** as a 1:1 mixture of diastereomers, while under the Sharpless asymmetric epoxidation conditions lomatiol afforded compounds **18** and **19** in 2:3 diastereomeric ratio. On bromination, lomatiol afforded monobrominated compounds **20**, **21**, **22**, and **23** (Eyong et al. 2015a).

These naphthoquinones together with some previously isolated and synthesized quinone derivatives were screened for their cytotoxicity, including 7-methoxy-2-acetylfuronapthoquinone (**24**), 2,3-dihydro-6-hydroxy-2-(prop-1-en-2-yl)naphtha[2,3-b]furan-4,9-dione (**25**), 2-acetylfuronapthoquinone (**4**), knipholone (**26**), knipholone anthrone (**27**), 3-hydroxydehydroiso-α-lapachone (**28**), 2-(prop-1-en-2-yl)naphtha[2,3-b]furan-4,9-dione (**29**), 3,4 dehydro-α-lapachone (**30**), tithoniamarin (**31**), new-bouldiaquinone (**32**), acetyllapachol (**33**), 4-(1,4-dihydro-2-hydroxy-1,4-dioxonaphthalen-3-yl)-2-methylbut-2-enal (**34**), 2-hydroxy-3-(4,4-dimethoxy-3-methylbutyl)naphthalene-1,4-dione (**35**), 1,4-dihydro-2-((3-(hydroxymethyl)-3-methyloxiran-2-yl)methyl) 1,4-dioxonaphthalen-3-yl acetate (**36**), 4-(1,4-dihydro-2-hydroxy-1,4-dioxonaphthalen-3-yl)-2-methylbutanal (**37**), acetyllomatiol (**38**), methoxy lomatiol (**39**), 1,4-dihydro-2-((3-(hydroxymethyl)-3-methyloxiran-2-yl)methyl)-1,4-dioxonaphthalen-3-yl acetate (**40**), lapachol-OMe (**41**), 1a-methoxy-7a-(3-methylbut-2-en-1-yl)-1a,7a-dihydronaphtho[2,3-b]oxirene-2,7-dione (**42**), 6-hydroxy-6-(3-methylbut-2-enyl)benzo[a]phenazin-5(6H)-one (**43**), β-lapachone-o-phenylene diamine (**44**), and 3-bromo-5-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromene-6 carbaldehyde (**45**) (Eyong et al. 2005, 2006, 2008 2013, 2015a, 2015b; Kuete et al. 2007; Induli et al. 2013) (Fig. 2).

## Cytotoxic activity

The compounds were evaluated in a panel (Dasari et al. 2015; Zhao et al. 2015) of human cell lines containing in vitro models for cancers typically associated with dismal prognosis, such as BE(2)-C, Kelly, SKNSH, CHLA-90 (all neuroblastoma) (Esposito et al. 2017; Zhao et al. 2016), A549 (non-small cell lung cancer) (Rossi et al. 2017), SKMEL-28 (melanoma) (Amann et al. 2017), and U373 (glioblastoma) (Osuka and Van Meir 2017).

First, the compounds were tested at a single concentration of 10 μM and the percent residual growth of cancer cells was recorded after a 72-h treatment (Table 2).

In most cases, the active compounds did not discriminate between the cell lines used with the exception of a few, such as β-lapachone derivative **21**, which was essentially inactive in three neuroblastoma cell lines, yet showed potent activity against the other cell lines in the panel.

Fourteen of the most potent compounds were then selected and evaluated against A549, SKMEL-28, and U373 cell lines to determine their $IC_{50}$ values (Table 3). Most of these compounds possess the β-naphthoquinone and the α-naphthoquinono[2,3-b]furan structural skeletons. Indeed, a literature search reveals a significant number of reports describing antiproliferative properties of compounds in these classes (Rios-Luci et al. 2012; Yamashita et al. 2007). Our results show that submicromolar to single digit micromolar $IC_{50}$ values are associated with compounds in which the β-naphthoquinone ring is fused with a saturated pyran (**2**, **11**, **20**, **21**) or a furan (**6**, **22**, **23**) moiety.

In the α-naphthoquinono[2,3-b]furan derivatives, the furan ring can be aromatic (**4**, **24**, **29**) or saturated (**16 and 28**) and retain activity, exhibiting submicromolar to low micromolar $IC_{50}$ values. Within the α-naphthoquinono[2,3-b]furan class, the acetyl furan **4** led to the highest cytotoxic activity indicating that the carbonyl of the acetoxyl group on the furan ring may play an important role in bioactivity (cf. isopropylidene furan **29**).

Knipholone anthrone (**27**) exhibited a mean $IC_{50}$ of ca. 1 μM, a value that is consistent with the literature data (Habtemariam 2010). It should be noted that this compound was recently found to induce necrotic cell death in cancer cells, identifying it as a promising anticancer agent to fight cancers with intrinsic resistance to apoptosis (Kornienko et al. 2013; Aksenov et al. 2015). Activity was found in the indeno[1,2-b]pyran skeleton, as represented with the product of the benzilic acid rearrangement, dione **9**, showing submicromolar to single digit micromolar potency depending on the cell line tested.

## Conclusion

In this study, the cytotoxic activity of some previously isolated quinones and derivatives of lapachol, which are structurally related to known anticancer agents (i.e. β-lapachone, α-lapachone, and 2-acetylfuronaphthoquinone), and two new indeno[1,2-b]pyran derivatives were evaluated in a panel of human cancer cell lines. Fourteen of the tested compounds were most active with submicromolar to low micromolar $IC_{50}$ values. Among these compounds, seven are based on the β-naphthoquinone and five on the α-naphthoquinono[2,3-b]furan structural skeletons. These results are comparable with values described in the literature for these classes of compounds (Rios-Luci et al. 2012; Yamashita et al. 2007). Among the two new indeno [1,2-b]pyran derivatives, the further oxidized, benzilic acid rearrangement product, dione **9** was the most interesting finding given that anticancer activity with this structural skeleton appears to be unprecedented. Given the ease of synthesis and potent cytotoxic activity of dione **9** from commercially available lapachol (**1**), this tricyclic pyranone-fused indenone represents a compelling starting

Medicinal Chemistry Research

**Fig. 2** Previously isolated and synthesized quinone derivatives



4   R = O
29  R = CH₂

5

6

7

11

12

13

14

15

16
19

17
18

20
21

22
23

24

25

26  R = C(O)
27  R = CH₂

28

30

31

33  R = CH₃
34  R = CHO

32

35

36

37

38  R = OAc
39  R = OMe

40

41

42

43

44

45

**Table 2** Percent residual growth of cancer cell lines after a 72 h of treatment with 10 μM of each compound as determined by the colorimetric MTT assay

| Compound | Residual growth (%) | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | BE(2)-C | Kelly | SKNSH | CHLA-90 | A549 | SKMEL-28 | U373 | Mean |
| 1 | 77 | 89 | 81 | 95 | 83 | 75 | 73 | 82 |
| 2 | 1 | 6 | 1 | 2 | 2 | 3 | 4 | 3 |
| 4 | 2 | 1 | 28 | 5 | 2 | 2 | 4 | 6 |
| 5 | 81 | 68 | 82 | 88 | 72 | 83 | 61 | 76 |
| 6 | 2 | 1 | 1 | 2 | 2 | 1 | 5 | 2 |
| 7 | 95 | 82 | 93 | 94 | 102 | 94 | 82 | 92 |
| 8 | 93 | 81 | 96 | 98 | 67 | 88 | 70 | 85 |
| 9 | 3 | 3 | 2 | 3 | 2 | 3 | 6 | 3 |
| 10 | 13 | 88 | 88 | 89 | NT[a] | NT | NT | 69 |
| 11 | 2 | 2 | 1 | 1 | 1 | 1 | 4 | 2 |
| 12 | 95 | 82 | 93 | 94 | 85 | 78 | 71 | 85 |
| 13 | 101 | 48 | 80 | 86 | 101 | 110 | 99 | 89 |
| 14 | 90 | 59 | 92 | 86 | 74 | 75 | 63 | 77 |
| 15 | 91 | 76 | 99 | 98 | 69 | 94 | 63 | 84 |
| 16 | 1 | 1 | 1 | 3 | 2 | 3 | 6 | 2 |
| 17 | 83 | 66 | 89 | 96 | NT | NT | NT | 83 |
| 18 | 38 | 76 | 74 | 85 | 78 | 87 | 74 | 73 |
| 19 | 1 | 2 | 2 | 3 | NT | NT | NT | 2 |
| 20 | 4 | 4 | 2 | 2 | 1 | 2 | 6 | 3 |
| 21 | 2 | 97 | 74 | 87 | 1 | 2 | 4 | 38 |
| 22 | 28 | 95 | 79 | 86 | 13 | 7 | 65 | 53 |
| 23 | 1 | 2 | 2 | 32 | 1 | 3 | 5 | 7 |
| 24 | 3 | 4 | 4 | 5 | 2 | 2 | 5 | 4 |
| 25 | 37 | 69 | 76 | 66 | 29 | 18 | 39 | 47 |
| 26 | 93 | 65 | 101 | 96 | 64 | 68 | 74 | 80 |
| 27 | 2 | 5 | 95 | 7 | 3 | 4 | 14 | 19 |
| 28 | 6 | 69 | 57 | 65 | 2 | 3 | 37 | 34 |
| 29 | 1 | 44 | 58 | 34 | 1 | 2 | 31 | 25 |
| 30 | 68 | 79 | 88 | 96 | 88 | 63 | 86 | 81 |
| 31 | 82 | 65 | 93 | 85 | 78 | 76 | 94 | 82 |
| 32 | 76 | 79 | 88 | 95 | 40 | 48 | 77 | 72 |
| 33 | 24 | 84 | 81 | 97 | 66 | 76 | 48 | 68 |
| 34 | 87 | 61 | 89 | 93 | 56 | 67 | 56 | 73 |
| 35 | 85 | 73 | 92 | 94 | 67 | 66 | 65 | 78 |
| 36 | 78 | 89 | 87 | 98 | 51 | 64 | 78 | 78 |
| 37 | 36 | 99 | 80 | 91 | 17 | 77 | 72 | 67 |
| 38 | 9 | 84 | 91 | 97 | 58 | 80 | 58 | 68 |
| 39 | 16 | 77 | 62 | 74 | 59 | 20 | 64 | 53 |
| 40 | 2 | 35 | 54 | 29 | 3 | 3 | 41 | 24 |
| 41 | 58 | 91 | 85 | 94 | 93 | 77 | 84 | 83 |
| 42 | 4 | 88 | 87 | 101 | 78 | 98 | 78 | 76 |
| 43 | 92 | 64 | 90 | 89 | 67 | 84 | 73 | 80 |
| 44 | 94 | 75 | 89 | 88 | 77 | 68 | 78 | 81 |
| 45 | 72 | 90 | 66 | 85 | NT | NT | NT | 78 |

[a]Not tested

**Table 3** In vitro growth inhibition (IC$_{50}$) after a 72 h of treatment with each compound as determined by the colorimetric MTT assay

| Compound | Structural skeleton | IC$_{50}$ (μM) | | | | |
|---|---|---|---|---|---|---|
| | | A549 | SKMEL-28 | U373 | IC$_{50}$ ± SEM | |
| **2** | β-naphthoquinone | 0.03 | 0.05 | 0.24 | 0.1 | 0.07 |
| **11** | β-naphthoquinone | 3 | 2 | 2 | 2.2 | 0.2 |
| **20** | β-naphthoquinone | 3 | 3 | 2 | 2 | 0.4 |
| **21** | β-naphthoquinone | 2 | 1 | 1 | 1.4 | 0.5 |
| **6** | β-naphthoquinone | 3 | 2 | 3 | 2.5 | 0.1 |
| **22** | β-naphthoquinone | 5 | 2 | NT | 3.5 | 1.3 |
| **23** | β-naphthoquinone | 0.3 | 0.4 | 2.2 | 1.0 | 0.6 |
| **4** | α-naphthoquinono[2,3-b]furan | 0.01 | 0.02 | 0.22 | 0.09 | 0.07 |
| **24** | α-naphthoquinono[2,3-b]furan | 0.2 | 0.3 | 2 | 0.9 | 0.7 |
| **29** | α-naphthoquinono[2,3-b]furan | 3 | 2 | NT | 2.4 | 0.4 |
| **16** | α-naphthoquinono[2,3-b]furan | 2 | 3 | 3 | 2.6 | 0.2 |
| **28** | α-naphthoquinono[2,3-b]furan | 3 | 3 | 3 | 3.0 | 0.0 |
| **27** | anthrone | 0.1 | 2 | 2 | 1.1 | 0.5 |
| **9** | indeno[1,2-b]pyran | 0.8 | 0.6 | 2.0 | 1.1 | 0.5 |

point for further derivative synthesis and mode of action studies.

## Experimental

### Synthetic procedures

#### Synthesis of 2,2-dimethyl-2,3-dihydroindeno[1,2-b]pyran-4,5-dione (9) and methyl 5-hydroxy-2,2-dimethyl-2,3,4,5-tetrahydroindeno[1,2-b]pyran-5-carboxylate (10)

To a stirred solution of lapachol (**1**), (242 mg, 1.0 mmol, 1 equiv) in CH$_2$Cl$_2$ (7 mL) was added conc. H$_2$SO$_4$ (0.8 ml, 1.5 mmol, 1.5 equiv), the resulting reaction mixture was stirred for 3 h, at room temperature. The orange suspension was filtered and washed with ice cold water (3 × 5 ml), the crude product was dried under vacuum and column chromatographic purification of the crude compound over silica gel using 20–30% EtOAc in hexane as solvent gradient afforded pure β-lapachone (**2**) (218 mg, 90% yield), as an orange solid (Eyong et al. 2013).

A solution of β-lapachone (**2**) (50 mg, 0.2 mmol) in acetonitrile (2 ml) at 25 °C was treated with 3 N NaOH solution (1 ml). The resultant mixture was stirred for 10 h at 25 °C, then the mixture was acidified to pH 5 using 5% HCl (2 ml) and the solvent was removed under reduced pressure. The residue was diluted with water (5 ml) and CH$_2$Cl$_2$ (5 ml). The layers were separated, the aqueous layer was extracted with CH$_2$Cl$_2$ (2 × 5 ml) and the combined organic layer was dried over anhydrous Na$_2$SO$_4$. The solvent was removed under reduced pressure to give crude compound, which was purified by column chromatography over silica gel using 10–20% EtOAc in hexane as solvent gradient afforded pure compound **8** (43 mg, 80% yield) as a red solid (s).

Methylation of compound **8** with diazomethane. To a stirred slurry of 50% aq. KOH (10 ml) in Et$_2$O (5.0 ml) at 0 °C, N-nitroso-N-methylurea (22.5 mg, 0.16 mmol, 2 equiv) was added slowly. The resulting yellow colored organic layer containing diazomethane was separated, dried over KOH pellets, and added to compound **8** (20.8 mg, 0.08 mmol, 1 equiv) in Et$_2$O (2 ml), the reaction mixture was stirred for 2 h and the solvent was removed under reduced pressure. Column chromatographic purification of the crude products over silica gel using hexane-EtOAc gradient systems afforded the unexpected dione **9** (18.4 mg, 80% yield) and ester **10** (2.2 mg, 10% yield). dione **9**: $^1$H NMR (600 MHz, CDCl$_3$) 8.15 (m, 1H), 7.60 (m, 1H), 7.65 (m, 1H), 7.65 (m, 1H), 2.95 (s, 2H), 1.61 (s, 6H); $^{13}$C NMR (150 MHz, CDCl$_3$) δ 181.5, 175.9, 168.9, 134.6, 132.0, 131.1, 129.5, 128.1, 124.7, 115.1, 93.8, 39.5, 28.6, 28.6. LCMS (APCI+) m/z calcd for C$_{14}$H$_{13}$O$_3$ [M+H]+: 229.08592; found: 229.08606. Ester **10**: $^1$H NMR (400 MHz, CDCl$_3$) δ 8.05–8.04 (m, 2H), 7.70–7.68 (m, 2H), 4.14 (s, 3H), 2.70–2.66 (m, 2H), 1.75–1.65 (m, 2H) 1.29 (s, 6H). HRMS (ES+) m/z calcd for C$_{16}$H$_{19}$O$_4$ [M+H]+: 275.1278; found: 275.1297.

### Biological assays

#### Cell lines

BE(2)-C and SK-N-SH cells were purchased from the American Type Culture Collection (ATCC). Kelly cells

were obtained from the cell line repository at the Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio. CHLA-90 cells were obtained from Children's Oncology Group. The neuroblastoma cell lines were maintained in DMEM/F12 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (P/S) under standard cell culture conditions. The A549 cells (DSMZ) were cultured in RPMI culture medium supplemented with 10% heat-inactivated FBS. SKMEL-28 cells (ATCC) and U373 GBM cells (ECACC) were cultured in RPMI culture medium supplemented with 10% heat-inactivated FBS (Life Technologies code 10270106). Cell culture media were supplemented with 4 mM glutamine (Lonza code BE17-605E), 100 µg/ml gentamicin (Lonza code 17-5182), and P/S (200 units/ml and 200 µg/ml) (Lonza code 17-602E) at 37 °C with 5% $CO_2$.

## Cell proliferation assay

The effect of the investigated compounds on cell proliferation was determined by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) assay. The compounds were dissolved in DMSO or MeOH/$CH_2Cl_2$ at a concentration of either 10 or 50 mM prior to cell treatment. The cells were trypsinized and seeded at various cell concentrations depending on the cell type. The cells were grown for 24–72 h, treated with test compounds at required concentrations and incubated for 72 h in 100 or 200 µl media depending on the cell line used. The number of experiments and replicates varied depending on the cell line. Cells treated with 0.1% DMSO, 1% $CH_2Cl_2$, or 1% MeOH were used as a negative control. The effect of compound treatment on cell survival was evaluated by comparing compound-treated cells to cells treated with control using two-tailed student's $t$ test, with $p < 0.05$ considered as statistically significant. The $IC_{50}$ corresponds to the concentration of the compound of interest that reduces by 50% the growth of the cancer cell line of interest after having cultured it for 72 h in the presence of the compound in comparison to the untreated control condition.

## Compliance with ethical standards

## References

Aksenov AV, Smirnov AN, Magedov IV, Reisenauer MR, Aksenov NA, Aksenova IV, Pendleton AL, Nguyen G, Johnston RK, Rubin M, De Carvalho A, Kiss R, Mathieu V, Lefranc F, Correa J, Cavazos DA, Brenner AJ, Bryan BA, Rogelj S, Kornienko A, Frolova LV (2015) Activity of 2-Aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells. J Med Chem 58 (5):2206–2220

Amann VC, Ramelyte E, Thurneysen S, Pitocco R, Bentele-Jaberg N, Goldinger SM, Dummer R, Mangana J (2017) Developments in targeted therapy in melanoma. Eur J Surg Oncol 43(3):581–593

Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ (2000) Role of quinones in toxicology. Chem Res Toxicol 13 (3):135–160

Castellanos JRG, Prieto JM, Heinrich M (2009) Red Lapacho (Tabebuia impetiginosa)—a global ethnopharmacological comomodity? J Ethnopharmacol 121:1–13

Dahlin JL, Nissink JWM, Strasser JM, Francis S, Higgins LA, Zhou H, Zhang Z, Walters MA (2015) PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J Med Chem 58(5):2091–2113

Dasari R, De Carvalho A, Medellin DC, Middleton KN, Hague F, Volmar MNM, Frolova LV, Rossato MF, De La Chapa JJ, Dybdal-Hargreaves NF, Pillai A, Kälin RE, Mathieu V, Rogelj S, Gonzales CB, Calixto JB, Evidente A, Gautier M, Munirathinam G, Glass R, Burth P, Pelly SC, Van Otterlo WA, Kiss R, Kornienko A (2015) Wittig derivatization of sesquiterpenoid polygodial leads to cytostatic agents with activity against drug resistant cancer cells and capable of pyrrolylation of primary amines. Eur J Med Chem 103:226–237

da Silva Jr EN, de Souza MCBV, Pinto AV, Pinto MCFR, Goulart MOF, Barros FWA, Pessoa C, Costa-Lotufo LV, Montenegro RC, de Moraes MO, Ferreira VF (2007) Synthesis and potent antitumor activity of new arylamino derivatives of nor-beta-lapachone and nor-alpha-lapachone. Bioorg Med Chem 15:7035–7041

Esposito MR, Aveic S, Seydel A, Tonini GP (2017) Neuroblastoma treatment in the post-genomic era. J Biomed Sci 24(1):14

Eyong KO, Krohn K, Hussain H, Folefoc GN, Nkengfack AE, Schulz B, Hu Q (2005) Newbouldiaquinone and newbouldiamide: a new naphthoquinone– anthraquinone coupled pigment and a new ceramide from *Newbouldia laevis*. Chem Pharm Bull 53 (6):616–619

Eyong KO, Folefoc GN, Kuete V, Beng VP, Hussain H, Krohn K, Nkengfack AE, Saeftel M, Sarite SR, Achim H (2006) Newbouldiaquinone A: a naphthoquinone-anthraquinone ether coupled pigment, as a potential antimicrobial and antimalarial agent from *Newbouldia laevis*. Phytochemistry 67:605–609

Eyong KO, Kumar SM, Folefoc GN, Nkengfack AE, Baskaran S (2008) Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol. Bioorg Med Chem Lett 18:5387–5390

Eyong KO, Puppala M, Kumar PM, Lamshöft M, Folefoc GN, Spiteller M, Baskaran S (2013) A mechanistic study on the Hooker

oxidation: synthesis of novel indane carboxylic acid derivatives from lapachol. Org Biomol Chem 11:459–468

Eyong KO, Chinthapally K, SenthilKumar S, Lamshöft M, Folefoc GN, Baskaran S (2015a) Conversion of lapachol to lomatiol: synthesis of novel naphthoquinone derivatives. New J Chem 39:9611–9616

Eyong KO, Ketsemen LH, Ghansenyuy YS, Folefoc NG (2015b) Chemical constituents, the stereochemistry of 3-hydroxy furonaphthoquinones from the root bark of Newbouldia laevis Seem (Bignoniaceae), and screening against Onchocerca ochengi parasites. Med Chem Res 24:965–969

Fiorito S, Epifano F, Bruyère C, Mathieu V, Kiss R, Genovese S (2014) Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives. Bioorg Med Chem Lett 24:454–457

Habtemariam S (2010) Knipholone anthrone from *Kniphofia foliosa* induces a rapid onset of necrotic cell death in cancer cells. Fitoterapia 81(8):1013–1019

Hussain H, Krohn K, Ahmad VU, Miana GA, Green IR (2007) Lapachol: an overview. Arkivoc 2:145–171

Induli M, Gebru M, Abdissa N, Akala H, Wekesa I, Byamukama R, Heydenreic M, Murunga S, Dagne E, Yenesew A (2013) Antiplasmodial quinones from the rhizomes of Kniphofia foliosa. Nat Prod Commun 8(9):1261–1264

Kuete V, Eyong KO, Folefoc NG, Beng VP, Hussain H, Krohn K, Nkengfack AE (2007) Antimicrobial activity of the methanolic extract and of the chemical constituents isolated from *Newbouldia laevis*. Pharmazie 62:552–556

Kornienko A, Mathieu V, Rastogi SK, Lefranc F, Kiss R (2013) Therapeutic agents triggering nonapoptotic cancer cell death. J Med Chem 56(12):4823–4839

Li Y, Li CJ, Yu D, Pardee AB (2000) Potent induction of apoptosis by beta-lapachone in human multiple myeloma cell lines and patient cells. Mol Med 6(12):1008–1015

Lim SM, Jeong Y, Lee S, Im H, Tae HS, Kim BG, Park HD, Park J, Hong S (2015) Identification of β-Lapachone analogs as Novel MALT1 inhibitors to treat an aggressive subtype of diffuse large B-cell lymphoma. J Med Chem 58:8491–8502

Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG (1992) Quinone chemistry and toxicity. Toxicol Appl Pharmacol 112(1):2–16

Nepomuceno JC (2011) Lapachol and its derivatives as potential drugs for cancer treatment. iConcept Press, Brazil

Oliveira MF, Lemos TLG, Mattos MCD, Segundo TA, Santiago GMP, Braz-Filho R (2002) New enamine derivatives of lapachol and biological activity. An da Academia Brasileira de Ciências 74:211–221

Osuka S, Van Meir EG (2017) Overcoming therapeutic resistance in glioblastoma: the way forward. J Clin Invest 127(2):415–426

Perez-Sacau E, Dıaz-Penate RG, Estevez-Braun A, Ravelo AG, Garcıa-Castellano JM, Pardo L, Campillo M (2007) Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line. J Med Chem 50:696–706

Queiroz MLS, Valadares MC, Torello CO, Ramos AL, Oliveira AB, Rocha FD, Arruda VA, Accorei WR (2008) Comparative studies of the effects of *Tabebuia avellanedae* bark extract and beta-lapachone on the hematopoietic response of tumour-bearing mice. J Ethnopharmacol 117:228–235

Ramos-Perez C, Lorenzo-Castrillejo I, Quevedo O, Garcia-Luis J, Matos-Perdomo E, Medina-Coello C, Estevez-Braun A, Machin F (2014) Yeast cytotoxic sensitivity to the antitumour agent β-lapachone depends mainly on oxidative stress and is largely independent of microtubule- or topoisomerase- mediated DNA damage. Biochemical Pharmacol 92:206–219

Rios-Luci C, Bonifazi EL, Leon LG, Montero JC, Burton G, Pandiella A, Misico RI, Padron JM (2012) β-Lapachone analogs with enhanced antiproliferative activity. Eur J Medicinal Chem 53:264–274

Rossi A, Sacco PC, Santabarbara G, Sgambato A, Casaluce F, Palazzolo G, Maione P, Gridelli C (2017) Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. Expert Opin Pharmacother 18(2):151–163

Souza-Silva F, Nascimento SB, Bourguignon SC, Pereira BA, Carneiro PF, Da Silva WS, Alves CR, De Pinho RT (2014) Evidences for leishmanicidal activity of the naphthoquinone derivative epoxy-α-lapachone. Exp Parasitol 147:81–84

Sunassee SN, Veale CGL, Shunmoogam-Gounden N, Osoniyi O, Hendricks DT, Caira MR, de la Mare J-A, Edkins AL, Pinto AV, da Silva Jr EN, Davies-Coleman MT (2013) Cytotoxicity of lapachol, β-lapachone and related synthetic 1,4-napthoquinones against oesophageal cancer cells. Eur J Med Chem 62:98–110

Tanis SP, Chuang YH, Head DB (1988) Furans in synthesis. 8. Formal total syntheses of (.+-.)- and (+)-aphidicolin. J Org Chem 53:4929–4938

Ueda S (2005) The present invention relates to a novel compound possessing antitumor activity, and an antitumor agent comprising said compounds. US Patent 5663197

Yamashita M, Kaneko M, Iida A, Tokuda H, Nishimura K (2007) Stereoselective synthesis and cytotoxicity of a cancer chemopreventive naphthoquinone from *Tabebuia avellanedae*. Bioorg Med Chem Lett 17(23):6417–6420

Zhao Z, Ma X, Sung D, Li M, Kosti A, Lin G, Chen Y, Pertsemlidis A, Th H, Du L (2015) microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest. RNA Biol 12(5):538–554

Zhao Z, Ma X, Shelton SD, Sung DC, Li M, Hernandez D, Zhang M, Losiewicz MD, Chen Y, Pertsemlidis A, Yu X, Liu Y, Du L (2016) A combined gene expression and functional study reveals the crosstalk between N-Myc and differentiation-inducing microRNAs in neuroblastoma cells. Oncotarget 7:79372–79387